Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 13, 2025
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2025 and provided a business update.
Read more at globenewswire.com
